23 Results for "

MHCI

" in MedChemExpress (MCE) Product Catalog:
Products (23)

23 Results for "MHCI" in MCE Product Catalog:

  • Isoforms Recommended:
49
49 Cited Publications
Cat. No.: HY-123606
CAS No.: 1652629-23-6
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8 + T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions .
1
1 Cited Publications
Cat. No.: HY-158301
CAS No.: 2929308-79-0
Purity:  99.94%
MY-1B is a covalent inhibitor of the RNA Methyltransferase NSUN2 (IC50: 1.3 μM). MY-1B stereoselectively ligands active-site cysteine residues (C271) of NSUN2. MY-1B can stereoselectively and covalently bind to PSME1, disrupting the proteasome regulatory complex and downregulating the presentation of specific MHC-I subtypes .
Cat. No.: HY-D1474
CAS No.: 33628-03-4
Target:  

Wnt

Research Areas:  

Cancer

WNT7A-IN-1 sodium (1365-0109), a WNT7A inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 sodium significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin . WNT7A-IN-1 sodium (compound F) is also a photographic sensitizer in the green spectral region .
Cat. No.: HY-171860
CAS No.: 3066894-28-5
Target:  

PROTACs HIV

Research Areas:  

Infection Cancer

FC-14369 is a PROTAC degrader targeting the HIV-1 Nef protein, with a DC50 value of 160 nM. Through its bifunctional structure, FC-14369 binds to Nef and the Cereblon E3 ubiquitin ligase, induces Nef ubiquitination and proteasomal degradation, restores the expression of cell-surface CD4 and MHC-I, and inhibits HIV-1 replication. FC-14369 can be used in research on HIV infection and AIDS. FC-14369 is applicable to studies related to HIV-1 infection .
Cat. No.: HY-170411
CAS No.: 29133-39-9
Target:  

Wnt

Research Areas:  

Cancer

WNT7A-IN-1 (1365-0109), a WNT7A inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin. WNT7A-IN-1 (compound F) is also a photographic sensitizer in the green spectral region .
Cat. No.: HY-P990193

Target:  

MHC

Research Areas:  

Inflammation/Immunology

Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) is an anti-mouse MHC Class I (H-2Kd, H-2Dd) IgG2a monoclonal antibody. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can block the interaction between Ly49 and MHC-I. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can be used for the construction of acute lung injury models .
Cat. No.: HY-160151
Research Areas:  

Cancer

TP1L is a potent and selective T-cell protein tyrosine phosphatase (TC-PTP) PROTAC degrader, with a DC50 value of 35.8 nM. TP1L elevates the phosphorylation level of TC-PTP substrates including pSTAT1 and pJAK1. TP1L selectively enhances IFN-γ signaling and increases MHC-I expression. TP1L activates TCR signaling through increases phosphorylation of LCK. TP1L enhances CAR-T cell mediated tumor killing efficacy through activation of the CAR-T cells. TP1L can be used for the study of cancer. (Pink: TC-PTP ligand: (HY-138964), Blue: E3 ligase CRBN Ligand (HY-A0003), Black: Linker: (HY-140002)) .
Cat. No.: HY-175459
Target:  

PROTACs FAK

Research Areas:  

Inflammation/Immunology Cancer

PROTAC FAK degrader 3 is a selective FAK PROTAC degrader (DC50 = 1.08 nM). PROTAC FAK degrader 3 induces FAK degradation dependent on the ubiquitin-proteasome system and its binding to FAK and CRBN. PROTAC FAK degrader 3 upregulates MHC-I gene transcription and tumor cell surface expression by inhibiting the non-catalytic activity of FAK, leading to increased antigen presentation and activation of cytotoxic CD8 T cells. PROTAC FAK degrader 3 enhances in vivo anti-tumor activity by promoting MHC-I expression and enhancing T cell activation. PROTAC FAK degrader 3 can be used in cancer research targeting FAK degradation in ovarian cancer, hepatocellular carcinoma, and other cancers .
Cat. No.: HY-179211
Target:  

HSP MHC

Research Areas:  

Cancer

CliMB-325 is an HSP90 inhibitor that can induce MHC-I (EC50 = 498 nM) expression on the surface of CT26 murine colorectal cancer cells. CliMB-325 enhances T cell activation and exhibits lower toxicity. CliMB-325 can be used for the study of colorectal cancer .
Cat. No.: HY-171859
CAS No.: 3066893-65-7
Target:  

PROTACs HIV

Research Areas:  

Infection Cancer

FC-14367 is a PROTAC degrader targeting HIV-1 Nef protein. FC-14367 forms a ternary complex by binding Nef and Cereblon E3 ubiquitin ligase, inducing Nef ubiquitination and proteasomal degradation, restoring cell-surface CD4 and MHC-I expression and inhibiting HIV-1 replication. FC-14367 can be used in research on HIV infection and AIDS . (Black: Glycolic acid (HY-W015967); Blue: 2-(2,6-Dioxopiperidin-3-yl)phthalimidine (HY-138793))
Cat. No.: HY-P77753
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: HLA0201; MHC I; gp100; Glycoprotein 100; ME20-M; P100
Species:  
Source:  
Cat. No.: HY-P77754
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: HLA0201; MHC I; gp100; Glycoprotein 100; ME20-M; P100
Species:  
Source:  
Cat. No.: HY-P77769
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: Survivin; MHC; MHC I; BIRC5; API4; EPR-1; IAP4; survivin variant 3 alpha
Species:  
Source:  
Cat. No.: HY-P77750
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: HLA0201; MHC I; MAGE-A4; CT1.4; MAGE4A; MAGE4B; MAGE-X2; member 4
Species:  
Source:  
Cat. No.: HY-P77752
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: HLA0201; MHC I; MAGE-A4; CT1.4; MAGE4A; MAGE4B; MAGE-X2; member 4
Species:  
Source:  
Cat. No.: HY-P77770
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: Survivin; MHC; MHC I; BIRC5; API4; EPR-1; IAP4; survivin variant 3 alpha
Species:  
Source:  
Cat. No.: HY-P700944
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Survivin; MHC; MHC I; BIRC5; API4; EPR-1; IAP4; survivin variant 3 alpha
Species:  
Source:  
Cat. No.: HY-P11397
CAS No.: 176510-49-9
Target:  

MHC

Research Areas:  

Cancer

VLPDVFIRCV, a melanoma antigen-derived peptide, is the intron sequence (nt 38-67) of the N-acetylglucosamine transferase V (GnT-V) gene. VLPDVFIRCV has a high affinity for MHC-I class molecules, but it cannot activate the immune response against natural tumor cells. The cytotoxic T lymphocytes (CTL) induced by VLPDVFIRCV can specifically lyse T2 cells loaded with this peptide in the chromium release experiment. VLPDVFIRCV can be used for vaccine design research .
Cat. No.: HY-P77751
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: HLA0201; MHC I; MAGE-A4; CT1.4; MAGE4A; MAGE4B; MAGE-X2; member 4
Species:  
Source:  
Cat. No.: HY-P700909
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A*24:02; HLA-A2402; MHC I; gp100; Glycoprotein 100; ME20-M; P100; GP100 Intron 4; Intron 4
Species:  
Source: